198 related articles for article (PubMed ID: 12184306)
1. FDA approves restricted marketing of Lotronex.
FDA Consum; 2002; 36(4):4. PubMed ID: 12184306
[No Abstract] [Full Text] [Related]
2. Contemporary thoughts on the treatment of irritable bowel syndrome.
Giaquinta D
Manag Care Interface; 2002 Aug; 15(8):19-20, 22. PubMed ID: 12229060
[No Abstract] [Full Text] [Related]
3. Lotronex and the FDA: a fatal erosion of integrity.
Horton R
Lancet; 2001 May; 357(9268):1544-5. PubMed ID: 11377636
[No Abstract] [Full Text] [Related]
4. FDA advisory panels recommend Lotronex be put back on market.
Charatan F
BMJ; 2002 May; 324(7345):1053. PubMed ID: 11993482
[No Abstract] [Full Text] [Related]
5. Irritable bowel syndrome. A poorly understood disorder.
Lewis C
FDA Consum; 2001; 35(4):30-6. PubMed ID: 11692885
[No Abstract] [Full Text] [Related]
6. FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky.
Horwitz BJ
Health News; 2002 Oct; 8(10):1-2. PubMed ID: 12416480
[No Abstract] [Full Text] [Related]
7. Lotronex(tm): therapy for diarrhea predominant irritable bowel syndrome.
McGahan L
Issues Emerg Health Technol; 2000 Oct; (11):1-5. PubMed ID: 11902219
[No Abstract] [Full Text] [Related]
8. A pill turned bitter. How a quest for a blockbuster drug went fatally wrong.
Shapiro JP
US News World Rep; 2000 Dec; 129(23):54-6. PubMed ID: 11126059
[No Abstract] [Full Text] [Related]
9. Lotronex withdrawn from market.
Harv Womens Health Watch; 2001 Feb; 8(6):6. PubMed ID: 11175468
[No Abstract] [Full Text] [Related]
10. FDA approves one drug for irritable bowel syndrome but suspends another.
Harv Womens Health Watch; 2008 Aug; 15(12):7. PubMed ID: 19115501
[No Abstract] [Full Text] [Related]
11. Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
Schiller LR; Johnson DA
Am J Gastroenterol; 2008 Apr; 103(4):815-9. PubMed ID: 18397418
[TBL] [Abstract][Full Text] [Related]
12. FDA approves Cimzia to treat Crohn's disease.
Lang L
Gastroenterology; 2008 Jun; 134(7):1819. PubMed ID: 18474249
[No Abstract] [Full Text] [Related]
13. Return of alosetron.
Hyman PE; Garvey TQ
Expert Opin Drug Saf; 2002 May; 1(1):1-4. PubMed ID: 12904154
[No Abstract] [Full Text] [Related]
14. FDA draws patients into alosetron risk management.
Miller JL
Am J Health Syst Pharm; 2000 Oct; 57(19):1736. PubMed ID: 11030021
[No Abstract] [Full Text] [Related]
15. FDA approves generic AZT for U.S. market.
O'Rourke M
AIDS Clin Care; 2005 Nov; 17(11):108. PubMed ID: 16323302
[No Abstract] [Full Text] [Related]
16. From the Food and Drug Administration.
Crawford LM
JAMA; 2002 Aug; 288(6):688. PubMed ID: 12169049
[No Abstract] [Full Text] [Related]
17. FDA advisers warn of more deaths if drug is relaunched.
Moynihan R
BMJ; 2002 Sep; 325(7364):561. PubMed ID: 12228121
[No Abstract] [Full Text] [Related]
18. Alosetron use drops dramatically with risk management.
Traynor K
Am J Health Syst Pharm; 2004 Jun; 61(12):1210-2. PubMed ID: 15259746
[No Abstract] [Full Text] [Related]
19. Alosetron to return to market.
Young D
Am J Health Syst Pharm; 2002 Jul; 59(14):1323-4. PubMed ID: 12132555
[No Abstract] [Full Text] [Related]
20. FDA approves Hep C drugs.
AIDS Alert; 2004 Jun; 19(6):71. PubMed ID: 15272452
[No Abstract] [Full Text] [Related]
[Next] [New Search]
